Full Press Release Details
Ainos Elects Ms. Hui-Lan (Celia) Wu as CFO, Lawrence K. Lin as
Executive Vice President of Operations, and Other Key
SAN DIEGO, CA / ACCESSWIRE / August 16, 2021 / Ainos, Inc.
("we", "our", or the "Company"), (OTC PINK:AIMD), elected Ms.
Hui-Lan (Celia) Wu as its new Chief Financial Officer
( CFO ). Ms. Wu succeeds Mr. Chun-Hsien Tsai who resigned from his CFO
position but continues to serve as the Company's Chairman of
Board, President, and Chief Executive Officer.
As we ramp up our operations to address the global need for
rapid disease testing, Ainos will greatly benefit from Celia
Wu's nearly thirty years of accounting, audit and management
consulting experience, Mr. Tsai remarked.
startup companies at the Center of Industry Accelerator and Patent
Strategy at the National Yang Ming Chiao Tung University
and has devoted herself to promote impact investing in
Taiwan, he further noted.
Before joining Ainos, Celia was a partner at KPMG Taiwan
where she provided audit services to private and public
companies in the technology, medical and chemical material sectors.
Celia Wu received her Executive MBA from National Yang
Ming Chiao Tung University and is a Certified Public
Accountant in Taiwan and China.
are also pleased that Lawrence Lin will continue his service to the
Company as Executive Vice President of Operations, Mr. Tsai
said. Prior to his appointment Mr. Lin served as Executive Advisor
to the Chairman of the Company. Mr. Lin brings more
than 30 years of global cross-border strategic management
consulting and financial investment experience at leading
institutional corporates such as Andersen Consulting, Salomon Smith
Barney, and Credit Suisse First Boston. Mr. Lin has a dual MBA in
Finance & International Business from New York University-
Stern School of Business.
will continue to invest in key executives and personnel to help us
reach the global scale necessary to execute our global health
mission, Mr. Tsai said.
addition, Mr. John Junyong Lee, Esq., was re-appointed as Chief
Legal Counsel and Corporate Secretary of the Company. Mr. Lee has
diverse experience in federal compliance and corporate governance
matters in addition to extensive work in investment and
transactional structuring, licensing and technology transfers,
joint ventures and foreign direct investments in the U.S. and
internationally. Mr. Lee received his Bachelor of Arts degree in
International Relations from Claremont McKenna College, Juris
Doctorate degree from the Columbus School of Law, The Catholic
University of America, and is licensed to practice law in the
District of Columbia.
Chih-Heng (Jack) Lu, was appointed as Corporate Secretary to serve
the Board and Company's Taiwan Branch Office. Mr. Lu concurrently serves as the Director of
Corporate Development for the Company. He previously served as
Chief Financial Officer of Taiwan Carbon Nano Technology Co., and
as Director of Daiwa Capital Markets and Director of CIMB Group,
Royal Bank of Scotland, and ABN AMRO.
Inc., a Texas corporation (f/k/a Amarillo Biosciences, Inc.), is a
diversified healthcare company engaged in the discovery and
development of pharmaceutical and biotech products. Our goal is to
introduce novel products that actively stimulate and rejuvenate the
human body to combat disease and enhance the ability to heal. The
Company is currently focusing on point-of-care testing rapid test
kit products that include diagnostics for COVID-19
(SARS-CoV2-Antigen Rapid Test), pneumonia, vaginitis and
helicobacter pylori (H. pylori) bacterial infection. The Company
currently has offices in the United States and Taiwan.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
press release contains "forward-looking statements" within the
meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as "anticipate,"
"believe," "estimate," "expect," "intend," "plan," "predict,"
"project," "target," "future," "seek," "likely," "strategy," "may,"
"should," "will," and similar references to future periods.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations, and assumptions regarding the
future of our business, future plans and strategies, projections,
anticipated events and trends, the economy, and other future
conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks, and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results may differ
materially from those indicated in the forward-looking statements.
Therefore, you should not rely on any of these forward-looking
factors that could cause our actual results to differ materially
from those indicated in the forward-looking statements include,
among others, the following: the cost of production and sales
potential of the Covid-19 Test Kit; the impact of final approvals
from the Taiwan Food and Drug Administration for the Covid-19 Test
Kit subsequent to emergency use authorization; the Company's
limited cash and history of losses; the Company's ability to
achieve profitability; intense competition and rapidly advancing
technology in the Company's industry that may outpace its
technology; customer demand for the products and services the
Company develops; the impact of competitive or alternative
products, technologies and pricing; the Company's ability to
manufacture any products it develops; general economic conditions
and events and the impact they may have on the Company and its
potential customers, including but not limited to the impact of
Covid-19; the Company's ability to obtain adequate financing in the
future; the impact of promulgation and implementation of
regulations by the World Health Organization, the TFDA and by
foreign governmental authorities with functions similar to those of